secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0000950170-24-029249
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Therapeutics reports FY2023 net loss $66.4M, raises $95M in private placement, extends runway into 2027
--------------------------------------------------------------------------------

- Net loss $66.4M for 2023 ($12.40/share) vs $59.3M in 2022; cash $121.5M at year-end.
- $95M private placement at $15.13/share; co-led by Braidwell and Adage Capital; expected close March 13.
- LX2006 Cohort 2 shows positive frataxin increase; interim data from SUNRISE-FA expected mid-2024.
- LX2020 granted FDA Fast Track and Orphan Drug Designation; first patient dosing expected in 1H 2024.
- Cash runway extended to fund operations into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/0000950170-24-029249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/lxeo-20240311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer